Cited by 2,604Heart Failure Treatment and ManagementRenin-Angiotensin System StudiesHeart rate and cardiovascular health

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, John JV, Östergren, Jan, Swedberg, Karl, Granger, Christopher B, Held, Peter, Michelson, Eric L, Olofsson, Bertil, Yusuf, Salim, Pfeffer, Marc A·2003·The Lancet

DOI 10.1016/s0140-6736(03)14283-3

Open this paper in CoChat — free account

Abstract

Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when added to angiotensin-converting-enzyme (ACE) inhibitors in patients with chronic heart failure (CHF). We aimed to find out whether these drugs improve clinical outcome.Methods Between March, 1999, and November, 1999, we enrolled 2548 patients with New York Heart Association functional class II-IV CHF and left-ventricular ejection fraction 40% or lower, and who were being treated with ACE inhibitors. We randomly assigned patients candesartan (n=1276, target dose 32 mg once daily) or placebo (n=1272). At baseline, 55% of patients were also treated with beta blockers and 17% with spironolactone. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was done by intention to treat.Findings The median follow-up was 41 months. 483 (38%) patients in the candesartan group and 538 (42%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.85 [95% CI 0.75-0.96], p=0.011; covariate adjusted p=0.010). Candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for CHF. The benefits of candesartan were similar in all predefined subgroups, including patients receiving baseline beta blocker treatment.Interpretation The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)14283-3

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
Garg, R. (1995) · JAMA · doi:10.1001/jama.273.18.1450 · Cited by 1,993
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01683-7 · Cited by 1,909
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. J. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,595
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M. A., Hall, A. S., Murray, G. D., Torp-Pedersen, C. T., Ball, S. G., Pogue, J. M., Moyé, L. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
Self-citation
The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis
Cleland, J. G. F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,553
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Circulation · doi:10.1161/hc4901.102568 · Cited by 1,440
Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
Packer, M., O’Connor, C. M., Ghali, J. K., Pressler, M. L., Carson, P. E., Belkin, R. N., Miller, A. B., Neuberg, G. W., Frid, D. J., WERTHEIMER, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351504 · Cited by 1,194

Show all 38 references

Sorted by citations

Items 201–300 of 1,001

The Renin-Angiotensin-Aldosterone System and Heart Failure
SAYER, G. T., & Bhat, G. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.002 · Cited by 216
Economic Burden of Heart Failure in??the Elderly
Liao, L., Allen, L. A., & Whellan, D. J. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826060-00001 · Cited by 205
Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study
Takahashi, A., Takase, H., Toriyama, T., Sugiura, T., Kurita, Y., Ueda, R., & Dohi, Y. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl293 · Cited by 205
Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer
Boekhout, A. H., Gietema, J. A., Kerklaan, B. M., van Werkhoven, E. D., Altena, R., Honkoop, A. H., Los, M., Smit, W. M., Nieboer, P., Smorenburg, C. H., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1726 · Cited by 207
The pathophysiology of acute heart failure—Is it all about fluid accumulation?
Cotter, G., Felker, G. M., Adams, K. F., Milo‐Cotter, O., & O’Connor, C. M. (2007) · American Heart Journal · doi:10.1016/j.ahj.2006.02.038 · Cited by 199
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. J. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70147-7 · Cited by 199
Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists
Azizi, M., & Ménard, J. (2004) · Circulation · doi:10.1161/01.cir.0000131449.94713.ad · Cited by 195
Normal Reference Intervals for Cardiac Dimensions and Function for Use in Echocardiographic Practice: A Guideline from the British Society of Echocardiography
Harkness, A., Ring, L. S., Augustine, D. X., Oxborough, D., Robinson, S., & Sharma, V. (2020) · Echo Research and Practice · doi:10.1530/erp-19-0050 · Cited by 203
Contemporary Use of Digoxin in the Management of Cardiovascular Disorders
Gheorghiade, M., van Veldhuisen, D. J., & Colucci, W. S. (2006) · Circulation · doi:10.1161/circulationaha.105.560110 · Cited by 194
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
Ariti, C. A., Cleland, J. G. F., Pocock, S., Pfeffer, M. A., Swedberg, K. B., Granger, C. B., McMurray, J. J. V., Michelson, E. L., Östergren, J., & Yusuf, S. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.003 · Cited by 193
Self-citation
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals
The ARB Trialists Collaboration (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328344a7de · Cited by 196
Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Raebel, M. A. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 190
Cardiovascular drug therapy in the elderly: benefits and challenges
Fleg, J. L., Aronow, W. S., & Frishman, W. H. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.162 · Cited by 186
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)
Smith, S. C., Jr. (2019) · PubMed · doi:10.17615/vf9y-es17 · Cited by 185
Effect of ultrasound screening on the rate of first operative procedures for developmental hip dysplasia in Germany
von Kries, R., Ihme, N., Oberle, D., Lorani, A., Stark, R. G., Altenhofen, L., & Niethard, F. U. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14957-4 · Cited by 184
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca‐Fontán, F., Vecchio, L. D., Floege, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02418-0 · Cited by 189
Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction
Phillips, C. O., Kashani, A., Ko, D. T., Francis, G., & Krumholz, H. M. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.18.1930 · Cited by 183
G Protein-Coupled Receptors: A Century of Research and Discovery
Liu, S., Anderson, P. J., Rajagopal, S., Lefkowitz, R. J., & Rockman, H. A. (2024) · Circulation Research · doi:10.1161/circresaha.124.323067 · Cited by 196
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists
Kurtz, T. W., & Pravenec, M. (2004) · Journal of Hypertension · doi:10.1097/00004872-200412000-00003 · Cited by 182
Baseline Characteristics and Treatment of Patients in Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K. B., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.115 · Cited by 184
Self-citation
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice
Zannad, F. M., Stough, W. G., Rossignol, P., Bauersachs, J., McMurray, J. J. V., Swedberg, K. B., Struthers, A. D., Voors, A. A., Ruilope, L. M., Bakris, G. L., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs257 · Cited by 183
Self-citation
What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?
Campbell, R. T., Jhund, P. S., Castagno, D., Hawkins, N. M., Petrie, M. C., & McMurray, J. J. V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.064 · Cited by 180
Self-citation
Therapeutic targets for cardiac fibrosis: from old school to next-gen
Travers, J. G., Tharp, C. A., Rubino, M., & McKinsey, T. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148554 · Cited by 179
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial
Hien, T. T., Dolecek, C., Phuong, P., Dung, N. T., Truong, N. T., Thai, L. H., An, D., Thanh, T. T., Stepniewska, K., White, N. J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15163-x · Cited by 176
Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors
Makani, H., Messerli, F. H., Romero, J., Wever-Pinzon, O., Korniyenko, A., Berrios, R. S., & Bangalore, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.034 · Cited by 175
Treatment of Hypertension in Patients With Coronary Artery Disease
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Hypertension · doi:10.1161/hyp.0000000000000018 · Cited by 180
The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases
Abraham, H. M. A., White, C. M., & White, W. B. (2014) · Drug Safety · doi:10.1007/s40264-014-0239-7 · Cited by 182
Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure
Castagno, D., Skali, H., Takeuchi, M., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Pfeffer, M. A., McMurray, J. J. V., & Solomon, S. D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.044 · Cited by 173
Self-citation
Effects of Telmisartan Added to Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients With Chronic Heart Failure
Cice, G., Benedetto, A. D., D’Isa, S., D’Andrea, A., Marcelli, D., Gatti, E., & Calabrò, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.105 · Cited by 172
Incidence and Predictors of Hyperkalemia in Patients With Heart Failure
Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.067 · Cited by 170
Self-citation
The apelin–APJ system in heart failure
Japp, A. G., & Newby, D. E. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.12.015 · Cited by 169
Echocardiographic Evaluation of Diastolic Function Can Be Used to Guide Clinical Care
Little, W. C., & Oh, J. K. (2009) · Circulation · doi:10.1161/circulationaha.109.869602 · Cited by 169
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s61438 · Cited by 171
ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4
Mori, J., Alrob, O. A., Wagg, C. S., Harris, R. A., Lopaschuk, G. D., & Oudit, G. Y. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00636.2012 · Cited by 169
Agonist-Induced Hypertrophy and Diastolic Dysfunction Are Associated With Selective Reduction in Glucose Oxidation
Mori, J., Basu, R., McLean, B. A., Das, S. K., Zhang, L., Patel, V. B., Wagg, C. S., Kassiri, Z., Lopaschuk, G. D., & Oudit, G. Y. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.966705 · Cited by 170
Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006
Krum, H., Jelinek, M. V., Stewart, S., Sindone, A. P., Atherton, J. J., & Hawkes, A. L. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00690.x · Cited by 167
Medical Treatment of Aortic Stenosis
Marquis‐Gravel, G., Redfors, B., Leon, M. B., & Généreux, P. (2016) · Circulation · doi:10.1161/circulationaha.116.023997 · Cited by 181
Leitlinien zur Therapie der chronischen Herzinsuffizienz
Hoppe, U. C., Böhm, M., Dietz, R., Hanrath, P., Kroemer, H. K., Osterspey, A., SCHMALTZ, A. A., & Erdmann, E. (2005) · Zeitschrift für Kardiologie · doi:10.1007/s00392-005-0268-4 · Cited by 181
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials
Ezekowitz, J. A., & McAlister, F. A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn543 · Cited by 167
Moderated ePoster Session 2
Butler, J., HAMO, C. E., Filippatos, G. S., Pocock, S., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.933 · Cited by 167
Association between antihypertensive treatment and adverse events: systematic review and meta-analysis
Albasri, A., Hattle, M., Koshiaris, C., Dunnigan, A. V., Paxton, B., Fox, S. E., Smith, M. C., Archer, L., Levis, B., Payne, R., et al. (2021) · BMJ · doi:10.1136/bmj.n189 · Cited by 170
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection
Werner, C. M., Baumhäkel, M., Teo, K. K., Schmieder, R. E., Mann, J. F. E., Unger, T., Yusuf, S., & Böhm, M. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0668-3 · Cited by 167
Self-citation
Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease
Mancini, G. B. J., Gosselin, G., Chow, B. J. W., Kostuk, W. J., Stone, J. A., Yvorchuk, K. J., Abramson, B. L., Cartier, R., Huckell, V. F., Tardif, J., et al. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.05.013 · Cited by 171
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
Packer, M., & McMurray, J. J. V. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2149 · Cited by 169
Self-citation
The Novel Biomarker Growth Differentiation Factor 15 in Heart Failure with Normal Ejection Fraction
Stahrenberg, R., Edelmann, F., Mende, M., Kockskämper, A., Düngen, H., Lüers, C., Binder, L., Herrmann‐Lingen, C., Gelbrich, G., Hasenfuss, G. P., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq151 · Cited by 167
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 166
The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction
McMurray, J. J. V., Solomon, S. D., Pieper, K. S., Reed, S. D., Rouleau, J. L., Velazquez, E. J., White, H. D., Howlett, J. G., Swedberg, K. B., Maggioni, A. P., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.055 · Cited by 163
Self-citation
Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
Segall, L., Nistor, I., & Covic, A. C. (2014) · BioMed Research International · doi:10.1155/2014/937398 · Cited by 164
Impaired glucose tolerance and impaired fasting glucose — a review of diagnosis, clinical implications and management
Petersen, J. L., & McGuire, D. K. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.007 · Cited by 159
Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation
Anand, K., Mooss, A. N., Hee, T. T., & Mohiuddin, S. M. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.01.007 · Cited by 159
Perioperative Management of Chronic Heart Failure
Groban, L., & Butterworth, J. F. I. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000226099.60493.d9 · Cited by 159
Heart failure
Krum, H., & Abraham, W. T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60236-1 · Cited by 166
Heart failure with preserved ejection fraction in the elderly: scope of the problem
Upadhya, B., Taffet, G. E., Cheng, C. P., & Kitzman, D. W. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.02.025 · Cited by 160
Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
Marcondes‐Braga, F. G., Moura, L. Z., Issa, V. S., Vieira, J. L., Rohde, L. E. P., Simões, M. V., Fernandes-Silva, M. M., Rassi, S., Martins, S. M., de Albuquerque, D. C., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210367 · Cited by 169
A Synthetic Non-degradable Polyethylene Glycol Hydrogel Retards Adverse Post-infarct Left Ventricular Remodeling
Dobner, S., Bezuidenhout, D., Govender, P., Zilla, P., & Davies, N. H. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.03.003 · Cited by 155
Effects of renin-angiotensin system inhibition end-organ protection: Can we do better?
WEIR, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.019 · Cited by 156
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias
Iravanian, S., & Dudley, S. C. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.02.025 · Cited by 157
Mouse strain determines the outcome of wound healing after myocardial infarction
van den Borne, S. W. M., van de Schans, V. A. M., Strzelecka‐Kiliszek, A., Vervoort-Peters, H. T. M., Lijnen, P. M., Cleutjens, J. P. M., Smits, J. F. M., Daemen, M. J. A. P., Janssen, B. J., & Blankesteijn, W. M. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp207 · Cited by 152
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G. L., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C. S., et al. (2011) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2011.06.001 · Cited by 151
Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction
van den Borne, S. W. M., Isobe, S., Verjans, J. W. H., Petrov, A. D., Løvhaug, D., Li, P., Zandbergen, H. R., Ni, Y., Frederik, P. M., Zhou, J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.067 · Cited by 150
Heart Failure with Preserved Ejection Fraction: Uncertainties and Dilemmas
Ferrari, R., Böhm, M., Cleland, J. G. F., Paulus, W. J., Pieske, B. M., Rapezzi, C., & Tavazzi, L. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.304 · Cited by 150
Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction
Bello, N. A., Claggett, B., Desai, A. S., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., & Solomon, S. D. (2014) · Circulation: Heart Failure · doi:10.1161/circheartfailure.113.001281 · Cited by 147
Self-citation
Novel RAAS agonists and antagonists: clinical applications and controversies
Romero, C. A., Orías, M., & Weir, M. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.6 · Cited by 148
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 147
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II – Therapy
Khan, N. A., McAlister, F. A., Rabkin, S. W., Padwal, R. S., Feldman, R. D., Campbell, N. R. C., Leiter, L. A., Lewanczuk, R. Z., Schiffrin, E. L., Hill, M. D., et al. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70280-x · Cited by 143
Therapeutic Targets in Heart Failure
Schelbert, E. B., Fonarow, G. C., Bonow, R. O., Butler, J., & Gheorghiade, M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.068 · Cited by 146
Management of Low Blood Pressure in Ambulatory Heart Failure with Reduced Ejection Fraction Patients
Cautela, J., Tartière, J., Solal, A. C., Bellemain-Appaix, A., Théron, A., Tibi, T., Januzzi, J. L., Roubille, F., & Girerd, N. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1835 · Cited by 143
Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials
Bangalore, S., Kumar, S., Wetterslev, J., & Messerli, F. H. (2011) · BMJ · doi:10.1136/bmj.d2234 · Cited by 137
Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction
Solomon, S. D., Shin, S., Shah, A. M., Skali, H., Desai, A. S., Køber, L., Maggioni, A. P., Rouleau, J. L., Kelly, R. Y., Hester, A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq522 · Cited by 136
Self-citation
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.10.009 · Cited by 139
The Prognostic Significance of Heart Failure with Preserved Left Ventricular Ejection Fraction: A Literature-Based Meta-Analysis
Somaratne, J., Berry, C., McMurray, J. J. V., Poppe, K., Doughty, R. N., & WHALLEY, G. A. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp103 · Cited by 135
Self-citation
Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers
Schmieder, R. E. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.11.032 · Cited by 137
An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure
Penn, M. S., Mendelsohn, F. O., Schaer, G. L., Sherman, W., FARR, M. A., Pastore, J., Rouy, D., Clemens, R., Aras, R. A., & Losordo, D. W. (2013) · Circulation Research · doi:10.1161/circresaha.111.300440 · Cited by 138
Treatment of Hypertension in Patients With Coronary Artery Disease
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.038 · Cited by 135
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition
van de Wal, R. M. A., Plokker, H. W. M., Lok, D. J. A., Boomsma, F., van der Horst, F. A. L., van Veldhuisen, D. J., van Gilst, W. H., & Voors, A. A. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.02.016 · Cited by 135
Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association
Schiele, F., Gale, C. P., Bonnefoy‐Cudraz, E., Capuano, F., Claeys, M. J., Danchin, N., Fox, K. A. A., Huber, K., Iakobishvili, Z., Lettino, M., et al. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616643053 · Cited by 134
Dilated Cardiomyopathy
Lakdawala, N. K., Winterfield, J. R., & Funke, B. (2012) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.111.962050 · Cited by 133
Association Between Cardiovascular vs. Non-Cardiovascular Co-Morbidities and Outcomes in Heart Failure with Preserved Ejection Fraction
Lund, L. H., Donal, E., Oger, E., Hage, C., Persson, H., Löfman, I. H., Ennezat, P., Sportouch, C., Drouet, É., Daubert, J., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.137 · Cited by 131
Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Malde, B., Regalado, J., & Greenberger, P. A. (2007) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)60860-5 · Cited by 131
Chronic Heart Failure
Morrissey, R. P., Czer, L. S. C., & Shah, P. K. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11592090-000000000-00000 · Cited by 131
Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor‐β
Edgley, A. J., Krum, H., & Kelly, D. J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00228.x · Cited by 134
Practical Recommendations for the Use of ACE Inhibitors, Beta-Blockers, Aldosterone Antagonists and Angiotensin Receptor Blockers in Heart Failure: Putting Guidelines into Practice
McMurray, J. J. V., Solal, A. C., Dietz, R., Eichhorn, E. J., Erhardt, L., Hobbs, R. F., Krum, H., Maggioni, A. P., McKelvie, R. S., Piña, I. L., et al. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.07.002 · Cited by 130
Self-citation
Safety and Tolerability of Angiotensin-Converting Enzyme Inhibitor Versus the Combination of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Patients With Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Lakhdar, R., Al-Mallah, M. H., & Lanfear, D. E. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.11.008 · Cited by 129
Is the Gap Between Guidelines and Clinical Practice in Heart Failure Treatment Being Filled? Insights from the IMPACT RECO Survey
de Groote, P., Isnard, R., Assyag, P., Clerson, P., Ducardonnet, A., Galinier, M., Jondeau, G., Leurs, I., Thébaut, J.-F., & Michel Komajda, N. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.09.008 · Cited by 129
Direct Renin Inhibition in Addition to or as an Alternative to Angiotensin Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale and Design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) Study
Krum, H., Massie, B. M., Abraham, W. T., Dickstein, K., Køber, L., McMurray, J. J. V., Desai, A., Gimpelewicz, C. R., Kandra, A., Reimund, B., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq212 · Cited by 129
Self-citation
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction
Martin, N., Manoharan, K., Thomas, J., Davies, C., & Lumbers, R. T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012721.pub2 · Cited by 131
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655761 · Cited by 130
Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)
Fried, L. F., Duckworth, W. C., Zhang, J. H., O’Connor, T., Brophy, M. T., Emanuele, N., Huang, G. D., McCullough, P. A., Palevsky, P. M., Seliger, S. L., et al. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03350708 · Cited by 128
Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure
Aronow, W. S. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000175289.87583.e5 · Cited by 124
Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency
Damman, K., Tang, W. H. W., Felker, G. M., Lassus, J., Zannad, F., Krum, H., & McMurray, J. J. V. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.031 · Cited by 122
Self-citation
Worsening Renal Function During Renin–Angiotensin–Aldosterone System Inhibitor Initiation and Long-Term Outcomes in Patients with Left Ventricular Systolic Dysfunction
Clark, H., Krum, H., & Hopper, I. (2013) · European Journal of Heart Failure · doi:10.1002/ejhf.13 · Cited by 125
Cardiac remodelling and RAS inhibition
Ferrario, C. M. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716642677 · Cited by 125
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA ( Vericiguat Global Study in Subjects with HFrEF ) trial
Voors, A. A., Mulder, H. S., Reyes, E. B., Cowie, M., Lassus, J. P. E., Hernandez, A. F., Ezekowitz, J. A., Butler, J., O’Connor, C. M., Koglin, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2221 · Cited by 126
AT1 Receptor Blocker Added to ACE Inhibitor Provides Benefits at Advanced Stage of Hypertensive Diastolic Heart Failure
Yoshida, J., Yamamoto, K., Mano, T., Sakata, Y., Nishikawa, N., Nishio, M., Ohtani, T., Miwa, T., Hori, M., & Masuyama, T. (2004) · Hypertension · doi:10.1161/01.hyp.0000118017.02160.fa · Cited by 122
Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease
Ferrario, C. M., & Mullick, A. E. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.020 · Cited by 126
Blockade of the renin–angiotensin–aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes
Burnier, M., & Zanchi, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000191244.91314.9d · Cited by 120
Angiotensin-Converting Enzyme Inhibitors
Izzo, J. L., & Weir, M. R. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00508.x · Cited by 124
The Incidence of Ischemic Stroke in Chronic Heart Failure: A Meta-Analysis
Witt, B. J., Gami, A. S., Ballman, K. V., Brown, R. D., Meverden, R. A., Jacobsen, S. J., & Roger, V. L. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.01.009 · Cited by 123
Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Raimondo, D. D., Tuttolomondo, A., Buttà, C., Miceli, S., Licata, G., & Pinto, A. V. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802481282 · Cited by 120
Diabetic cardiomyopathy
Lee, M. M. Y., McMurray, J. J. V., Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. A., Jhund, P. S., & Petrie, M. C. (2018) · Heart · doi:10.1136/heartjnl-2016-310342 · Cited by 121
Self-citation

Authors: McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A.
Affiliations: University of Glasgow (GB)
Karolinska University Hospital (SE)
Sahlgrenska University Hospital (SE)
Duke Medical Center (US)
AstraZeneca (Sweden) (SE)
AstraZeneca (United States) (US)
Hamilton Health Sciences (CA)
Brigham and Women's Hospital (US)
Corresponding author: McMurray, John JV
ORCID: McMurray, John JV
Östergren, Jan
Swedberg, Karl
Granger, Christopher B
Yusuf, Salim
Pfeffer, Marc A
Venue: The Lancet
Publisher: Elsevier BV
Published: 2003-09
Volume: 362
Issue: 9386
Pages: 767-771
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(03)14283-3
OpenAlex: W2098780362
Cited by: 2,604
References: 38
Citations by year: 2026: 8 · 2025: 15 · 2024: 46 · 2023: 52 · 2022: 58 · 2021: 60 · 2020: 98 · 2019: 82 · 2018: 66 · 2017: 103 · 2016: 108 · 2015: 118 · 2014: 122 · 2013: 126 · 2012: 153
FWCI: 122.65
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords: candesartan, chronic heart failure, reduced left ventricular ejection fraction, angiotensin receptor blockers, ACE inhibitors, combination therapy, cardiovascular mortality, beta-blockers, spironolactone
MeSH terms: Adolescent, Adult, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Cardiac Output, Low, Cardiovascular Diseases, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Placebos, Tetrazoles, Comorbidity, Treatment Outcome, Ventricular Dysfunction, Left, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks